ProfileGDS5678 / 1450378_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 81% 81% 81% 91% 82% 80% 82% 83% 82% 81% 81% 80% 81% 80% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.7484781
GSM967853U87-EV human glioblastoma xenograft - Control 25.8044681
GSM967854U87-EV human glioblastoma xenograft - Control 35.7771181
GSM967855U87-EV human glioblastoma xenograft - Control 47.589591
GSM967856U87-EV human glioblastoma xenograft - Control 56.0183982
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.4957480
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7595382
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0060983
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.936682
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.7752181
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.7597281
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7691680
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7793881
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.6185780